Agoracom

(http://www.amscanada.com)(AMS), a leading provider of aircraft data capture, reporting and innovative solutions to the global aviation industry, is pleased to announce it has initiated a development program with MBEC BioProducts Inc. (MBEC) of Edmonton, AB. for the disinfection of commercial passenger aircraft cabin surfaces. MBEC is a leader in research and development of the control or eradication of microbial biofilms.

Graham Bruce, AMS Research and Development Manager, stated, “the route of transmission of many medically important diseases is through microbial biofilms growing on everyday surfaces. MBEC has perfected unique methodologies in culturing biofilms, and testing the efficacy of biocides on these biofilms. Our objective is to offer airframe manufacturers, such as Boeing, and the airlines they sell their products to, an effective method of disinfecting their aircraft using biocides developed and tested by the patented MBEC technology. AMS would intend to patent the solutions developed in this process and sell directly to the airlines with the approval and support of the aircraft manufacturers. AMS is currently researching, with the support of a major aircraft manufacturer, biocides for use on aircraft interiors. When developed, it will be certified for use on the aircraft by the necessary regulatory bodies and the aircraft manufacturer.”

Darryl Jacobs, President of AMS stated “AMS is pleased to be working with MBEC BioProducts on this important project. We look forward to a long and prosperous partnership and can foresee a number of other significant development programs in the near future. The transmission of microbes on commercial flights has long been recognized as a problem by the travelling public. AMS is excited to work with our partners to reduce this inconvenience to travellers and the airlines.”

MBEC’s President, Ken Boutilier, said that he is “excited about the opportunity to participate in a project addressing a concern that has received significant recent public exposure. This project represents a good example of MBEC’s business strategy to make its unique technology available to potential customers from industries as diverse as pharmaceutical development, health management, all the way to development of biocides used for industrial maintenance.”

This press release is available on the AeroMechanical investor relations site for investor questions, commentary and feedback. Investors are asked to visit http://www.agoracom.com and select the AeroMechanical Investor Discussion and Contact Forum. Alternatively, investors can e-mail their questions or comments directly to AMA@agoracom.com or asked to be placed on the AeroMechanical investor e-mail list to receive all future press releases directly.

About AeroMechanical Services Ltd. http://www.amscanada.com

AeroMechanical Services is a Calgary based company that designs, builds, markets and supports innovative solutions for the global airline business. AMS is positioned to become the leader in the aviation data recording and reporting sector through its` innovative AFIRSTM data collection and transmission devices. AFIRSTM, in conjunction with Uptime TM, provides business-critical data to subscribers where and when they need it.

AeroMechanical also delivers an innovative Underfloor Stowage Unit, which provides significantly increased flight deck safety and utility to flight crews. Finally, the announcement of AirQTM , a ground breaking technology to effectively remove pathogens from the air-conditioning systems of aircraft, is receiving wide interest from the industry.

About MBEC BioProducts Inc. http://www.mbec.ca

MBEC is a private company that specializes in the assessment and eradication of microbial biofilms. Microbial biofilms are the leading cause of most chronic human infections. Biofouling problems found in industry and agriculture are also mainly the result of microbial biofilm formation. MBEC develops products and conducts contract research towards the prevention and eradication of these serious and costly problems. The MBEC Assayä is a patented, accurate, high-throughput screening system for in vitro growth of biofilms and subsequent testing of their susceptibility to antibiotics and biocides. It has application with pharmaceutical and biocide manufacturers in the discovery of new compounds, and in research. The company conducts contract research for the world’s leading manufacturers of catheters and other implanted medical devices. As well, MBEC contracts with other industries affected by microbial biofilms including municipal water systems, health regions, dental supply companies and wound healing companies. Subject to shareholder and regulatory approval, MBEC may be acquired by Innovotech Inc. (IOT.P – TSXV), a CPC on the TSX Venture Exchange.

Media Contacts:

Darryl Jacobs, President,

AeroMechanical Services Ltd

(403) 291-7434 djacobs@amscanada.com

Bill Tempany, CEO,

AeroMechanical Services Ltd

(403) 291-7436 btempany@amscanada.com

Ken Boutilier, President

MBEC BioProducts Inc.

(780) 452-8687 ken.boutilier@mbec.ca

AFIRS, UpTime and Smart Box are Trade Marks of AeroMechanical Services Ltd.

AeroMechanical Services Ltd.

TSX Venture Trading Symbol ``AMA``

A Tier 2 Industrial Issuer

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this Release.

Investor Relations Contact:

AGORA Investor Relations

Web: http://www.agoracom.com

E-mail: AMA@agoracom.com